Prognostic factors in primary diffuse large B-cell lymphoma of adrenal gland treated with rituximab-CHOP chemotherapy from the Consortium for Improving Survival of Lymphoma (CISL)

Yu Ri Kim, Jin Seok Kim, Yoo Hong Min, Dok Hyunyoon, Ho Jin Shin, Yeung Chul Mun, Yong Park, Young Rok Do, Seong Hyun Jeong, Joon Seong Park, Sung Yong Oh, Suee Lee, Eun Kyung Park, Joung Soon Jang, Won Sik Lee, Hwe Won Lee, Hyeonseok Eom, Jae Sook Ahn, Jae Heon Jeong, Sun Kyung Baek & 3 others Seok Jin Kim, Won Seog Kim, Cheolwon Suh

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

Background: The objective of this study was to identify prognostic factors for survival in patients with primary diffuse large B-cell lymphoma (DLBCL) of the adrenal gland. Methods: Thirty one patients diagnosed with primary adrenal DLBCL from 14 Korean institutions and treated with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone) were analyzed. Results: Complete remission (CR) and overall response rate after R-CHOP chemotherapy were 54.8% and 87.0%. The 2-year estimates of overall survival (OS) and progression-free survival (PFS) were 68.3% and 51.1%. In patients achieving CR, significant prolongations of OS (P = 0.029) and PFS (P = 0.005) were observed. Ann Arbor stage had no influence on OS. There was no significant difference in OS between patients with unilateral involvement of adrenal gland and those with bilateral involvement. When staging was modified to include bilateral adrenal involvement as one extranodal site, early stage (I or II) significantly correlated with longer OS (P = 0.021) and PFS (P <0.001). Conclusions: Contrary to prior reports, our data suggests that outcomes of primary adrenal DLBCL are encouraging using a regimen of R-CHOP, and that achieving CR after R-CHOP is predictive of survival. Likewise, our modified staging system may have prognostic value.

Original languageEnglish
Article number49
JournalJournal of Hematology and Oncology
Volume5
DOIs
Publication statusPublished - 2012 Aug 15

Fingerprint

Lymphoma, Large B-Cell, Diffuse
Adrenal Glands
Lymphoma
Drug Therapy
Survival
Disease-Free Survival
Vincristine
Prednisone
Rituximab
Doxorubicin
Cyclophosphamide

Keywords

  • Diffuse large B-cell lymphoma
  • Primary adrenal lymphoma
  • Prognostic factor
  • R-CHOP

ASJC Scopus subject areas

  • Hematology
  • Molecular Biology
  • Oncology
  • Cancer Research

Cite this

Prognostic factors in primary diffuse large B-cell lymphoma of adrenal gland treated with rituximab-CHOP chemotherapy from the Consortium for Improving Survival of Lymphoma (CISL). / Kim, Yu Ri; Kim, Jin Seok; Min, Yoo Hong; Hyunyoon, Dok; Shin, Ho Jin; Mun, Yeung Chul; Park, Yong; Do, Young Rok; Jeong, Seong Hyun; Park, Joon Seong; Oh, Sung Yong; Lee, Suee; Park, Eun Kyung; Jang, Joung Soon; Lee, Won Sik; Lee, Hwe Won; Eom, Hyeonseok; Ahn, Jae Sook; Jeong, Jae Heon; Baek, Sun Kyung; Kim, Seok Jin; Kim, Won Seog; Suh, Cheolwon.

In: Journal of Hematology and Oncology, Vol. 5, 49, 15.08.2012.

Research output: Contribution to journalArticle

Kim, YR, Kim, JS, Min, YH, Hyunyoon, D, Shin, HJ, Mun, YC, Park, Y, Do, YR, Jeong, SH, Park, JS, Oh, SY, Lee, S, Park, EK, Jang, JS, Lee, WS, Lee, HW, Eom, H, Ahn, JS, Jeong, JH, Baek, SK, Kim, SJ, Kim, WS & Suh, C 2012, 'Prognostic factors in primary diffuse large B-cell lymphoma of adrenal gland treated with rituximab-CHOP chemotherapy from the Consortium for Improving Survival of Lymphoma (CISL)', Journal of Hematology and Oncology, vol. 5, 49. https://doi.org/10.1186/1756-8722-5-49
Kim, Yu Ri ; Kim, Jin Seok ; Min, Yoo Hong ; Hyunyoon, Dok ; Shin, Ho Jin ; Mun, Yeung Chul ; Park, Yong ; Do, Young Rok ; Jeong, Seong Hyun ; Park, Joon Seong ; Oh, Sung Yong ; Lee, Suee ; Park, Eun Kyung ; Jang, Joung Soon ; Lee, Won Sik ; Lee, Hwe Won ; Eom, Hyeonseok ; Ahn, Jae Sook ; Jeong, Jae Heon ; Baek, Sun Kyung ; Kim, Seok Jin ; Kim, Won Seog ; Suh, Cheolwon. / Prognostic factors in primary diffuse large B-cell lymphoma of adrenal gland treated with rituximab-CHOP chemotherapy from the Consortium for Improving Survival of Lymphoma (CISL). In: Journal of Hematology and Oncology. 2012 ; Vol. 5.
@article{b5651b6e81bc4bf293bc0342c0f68c84,
title = "Prognostic factors in primary diffuse large B-cell lymphoma of adrenal gland treated with rituximab-CHOP chemotherapy from the Consortium for Improving Survival of Lymphoma (CISL)",
abstract = "Background: The objective of this study was to identify prognostic factors for survival in patients with primary diffuse large B-cell lymphoma (DLBCL) of the adrenal gland. Methods: Thirty one patients diagnosed with primary adrenal DLBCL from 14 Korean institutions and treated with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone) were analyzed. Results: Complete remission (CR) and overall response rate after R-CHOP chemotherapy were 54.8{\%} and 87.0{\%}. The 2-year estimates of overall survival (OS) and progression-free survival (PFS) were 68.3{\%} and 51.1{\%}. In patients achieving CR, significant prolongations of OS (P = 0.029) and PFS (P = 0.005) were observed. Ann Arbor stage had no influence on OS. There was no significant difference in OS between patients with unilateral involvement of adrenal gland and those with bilateral involvement. When staging was modified to include bilateral adrenal involvement as one extranodal site, early stage (I or II) significantly correlated with longer OS (P = 0.021) and PFS (P <0.001). Conclusions: Contrary to prior reports, our data suggests that outcomes of primary adrenal DLBCL are encouraging using a regimen of R-CHOP, and that achieving CR after R-CHOP is predictive of survival. Likewise, our modified staging system may have prognostic value.",
keywords = "Diffuse large B-cell lymphoma, Primary adrenal lymphoma, Prognostic factor, R-CHOP",
author = "Kim, {Yu Ri} and Kim, {Jin Seok} and Min, {Yoo Hong} and Dok Hyunyoon and Shin, {Ho Jin} and Mun, {Yeung Chul} and Yong Park and Do, {Young Rok} and Jeong, {Seong Hyun} and Park, {Joon Seong} and Oh, {Sung Yong} and Suee Lee and Park, {Eun Kyung} and Jang, {Joung Soon} and Lee, {Won Sik} and Lee, {Hwe Won} and Hyeonseok Eom and Ahn, {Jae Sook} and Jeong, {Jae Heon} and Baek, {Sun Kyung} and Kim, {Seok Jin} and Kim, {Won Seog} and Cheolwon Suh",
year = "2012",
month = "8",
day = "15",
doi = "10.1186/1756-8722-5-49",
language = "English",
volume = "5",
journal = "Journal of Hematology and Oncology",
issn = "1756-8722",
publisher = "BioMed Central",

}

TY - JOUR

T1 - Prognostic factors in primary diffuse large B-cell lymphoma of adrenal gland treated with rituximab-CHOP chemotherapy from the Consortium for Improving Survival of Lymphoma (CISL)

AU - Kim, Yu Ri

AU - Kim, Jin Seok

AU - Min, Yoo Hong

AU - Hyunyoon, Dok

AU - Shin, Ho Jin

AU - Mun, Yeung Chul

AU - Park, Yong

AU - Do, Young Rok

AU - Jeong, Seong Hyun

AU - Park, Joon Seong

AU - Oh, Sung Yong

AU - Lee, Suee

AU - Park, Eun Kyung

AU - Jang, Joung Soon

AU - Lee, Won Sik

AU - Lee, Hwe Won

AU - Eom, Hyeonseok

AU - Ahn, Jae Sook

AU - Jeong, Jae Heon

AU - Baek, Sun Kyung

AU - Kim, Seok Jin

AU - Kim, Won Seog

AU - Suh, Cheolwon

PY - 2012/8/15

Y1 - 2012/8/15

N2 - Background: The objective of this study was to identify prognostic factors for survival in patients with primary diffuse large B-cell lymphoma (DLBCL) of the adrenal gland. Methods: Thirty one patients diagnosed with primary adrenal DLBCL from 14 Korean institutions and treated with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone) were analyzed. Results: Complete remission (CR) and overall response rate after R-CHOP chemotherapy were 54.8% and 87.0%. The 2-year estimates of overall survival (OS) and progression-free survival (PFS) were 68.3% and 51.1%. In patients achieving CR, significant prolongations of OS (P = 0.029) and PFS (P = 0.005) were observed. Ann Arbor stage had no influence on OS. There was no significant difference in OS between patients with unilateral involvement of adrenal gland and those with bilateral involvement. When staging was modified to include bilateral adrenal involvement as one extranodal site, early stage (I or II) significantly correlated with longer OS (P = 0.021) and PFS (P <0.001). Conclusions: Contrary to prior reports, our data suggests that outcomes of primary adrenal DLBCL are encouraging using a regimen of R-CHOP, and that achieving CR after R-CHOP is predictive of survival. Likewise, our modified staging system may have prognostic value.

AB - Background: The objective of this study was to identify prognostic factors for survival in patients with primary diffuse large B-cell lymphoma (DLBCL) of the adrenal gland. Methods: Thirty one patients diagnosed with primary adrenal DLBCL from 14 Korean institutions and treated with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone) were analyzed. Results: Complete remission (CR) and overall response rate after R-CHOP chemotherapy were 54.8% and 87.0%. The 2-year estimates of overall survival (OS) and progression-free survival (PFS) were 68.3% and 51.1%. In patients achieving CR, significant prolongations of OS (P = 0.029) and PFS (P = 0.005) were observed. Ann Arbor stage had no influence on OS. There was no significant difference in OS between patients with unilateral involvement of adrenal gland and those with bilateral involvement. When staging was modified to include bilateral adrenal involvement as one extranodal site, early stage (I or II) significantly correlated with longer OS (P = 0.021) and PFS (P <0.001). Conclusions: Contrary to prior reports, our data suggests that outcomes of primary adrenal DLBCL are encouraging using a regimen of R-CHOP, and that achieving CR after R-CHOP is predictive of survival. Likewise, our modified staging system may have prognostic value.

KW - Diffuse large B-cell lymphoma

KW - Primary adrenal lymphoma

KW - Prognostic factor

KW - R-CHOP

UR - http://www.scopus.com/inward/record.url?scp=84864795374&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84864795374&partnerID=8YFLogxK

U2 - 10.1186/1756-8722-5-49

DO - 10.1186/1756-8722-5-49

M3 - Article

VL - 5

JO - Journal of Hematology and Oncology

JF - Journal of Hematology and Oncology

SN - 1756-8722

M1 - 49

ER -